nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—BRAF—skin cancer	0.354	1	CbGaD
Dabrafenib—RAF1—Vemurafenib—skin cancer	0.185	0.392	CbGbCtD
Dabrafenib—BRAF—Vemurafenib—skin cancer	0.155	0.328	CbGbCtD
Dabrafenib—ABCG2—Vismodegib—skin cancer	0.0222	0.047	CbGbCtD
Dabrafenib—ABCG2—Vemurafenib—skin cancer	0.0176	0.0372	CbGbCtD
Dabrafenib—SLCO1B3—Docetaxel—skin cancer	0.013	0.0276	CbGbCtD
Dabrafenib—CYP2C8—Vismodegib—skin cancer	0.0119	0.025	CbGbCtD
Dabrafenib—ABCG2—Dactinomycin—skin cancer	0.0117	0.0247	CbGbCtD
Dabrafenib—ABCB1—Vismodegib—skin cancer	0.00802	0.0169	CbGbCtD
Dabrafenib—ABCG2—Fluorouracil—skin cancer	0.0079	0.0167	CbGbCtD
Dabrafenib—CYP3A4—Temozolomide—skin cancer	0.00693	0.0146	CbGbCtD
Dabrafenib—CYP3A4—Imiquimod—skin cancer	0.00693	0.0146	CbGbCtD
Dabrafenib—ABCG2—Docetaxel—skin cancer	0.00603	0.0127	CbGbCtD
Dabrafenib—CYP3A4—Vismodegib—skin cancer	0.00481	0.0102	CbGbCtD
Dabrafenib—ABCB1—Dactinomycin—skin cancer	0.00421	0.0089	CbGbCtD
Dabrafenib—CYP2C8—Fluorouracil—skin cancer	0.00421	0.00889	CbGbCtD
Dabrafenib—CYP3A4—Vemurafenib—skin cancer	0.0038	0.00803	CbGbCtD
Dabrafenib—ABCB1—Docetaxel—skin cancer	0.00218	0.0046	CbGbCtD
Dabrafenib—CYP3A4—Docetaxel—skin cancer	0.0013	0.00275	CbGbCtD
Dabrafenib—NEK11—female reproductive system—skin cancer	0.00116	0.0919	CbGeAlD
Dabrafenib—RAF1—hair follicle—skin cancer	0.001	0.0798	CbGeAlD
Dabrafenib—RAF1—nipple—skin cancer	0.000681	0.0541	CbGeAlD
Dabrafenib—NEK11—lymph node—skin cancer	0.000676	0.0538	CbGeAlD
Dabrafenib—RAF1—neck—skin cancer	0.000674	0.0536	CbGeAlD
Dabrafenib—SIK1—connective tissue—skin cancer	0.000607	0.0482	CbGeAlD
Dabrafenib—SIK1—skin of body—skin cancer	0.000548	0.0436	CbGeAlD
Dabrafenib—SIK1—mammalian vulva—skin cancer	0.0005	0.0397	CbGeAlD
Dabrafenib—LIMK1—lymph node—skin cancer	0.000484	0.0385	CbGeAlD
Dabrafenib—RAF1—connective tissue—skin cancer	0.000483	0.0384	CbGeAlD
Dabrafenib—RAF1—epithelium—skin cancer	0.000459	0.0364	CbGeAlD
Dabrafenib—SIK1—lymphoid tissue—skin cancer	0.000444	0.0353	CbGeAlD
Dabrafenib—RAF1—skin of body—skin cancer	0.000436	0.0347	CbGeAlD
Dabrafenib—SIK1—female reproductive system—skin cancer	0.000428	0.034	CbGeAlD
Dabrafenib—RAF1—mammalian vulva—skin cancer	0.000398	0.0316	CbGeAlD
Dabrafenib—SIK1—head—skin cancer	0.000358	0.0284	CbGeAlD
Dabrafenib—RAF1—lymphoid tissue—skin cancer	0.000353	0.0281	CbGeAlD
Dabrafenib—RAF1—female reproductive system—skin cancer	0.000341	0.0271	CbGeAlD
Dabrafenib—BRAF—lymph node—skin cancer	0.000299	0.0238	CbGeAlD
Dabrafenib—RAF1—head—skin cancer	0.000285	0.0226	CbGeAlD
Dabrafenib—SLCO1B1—female reproductive system—skin cancer	0.000255	0.0203	CbGeAlD
Dabrafenib—SIK1—lymph node—skin cancer	0.00025	0.0199	CbGeAlD
Dabrafenib—RAF1—lymph node—skin cancer	0.000199	0.0158	CbGeAlD
Dabrafenib—ABCB1—blood vessel—skin cancer	0.000192	0.0153	CbGeAlD
Dabrafenib—SLC22A8—head—skin cancer	0.000165	0.0131	CbGeAlD
Dabrafenib—ABCG2—mammalian vulva—skin cancer	0.000165	0.0131	CbGeAlD
Dabrafenib—CYP2C8—female reproductive system—skin cancer	0.000145	0.0115	CbGeAlD
Dabrafenib—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000138	0.0012	CcSEcCtD
Dabrafenib—Haematuria—Bleomycin—skin cancer	0.000138	0.00119	CcSEcCtD
Dabrafenib—Hypertension—Imiquimod—skin cancer	0.000137	0.00119	CcSEcCtD
Dabrafenib—Arthralgia—Imiquimod—skin cancer	0.000135	0.00117	CcSEcCtD
Dabrafenib—Myalgia—Imiquimod—skin cancer	0.000135	0.00117	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000134	0.00116	CcSEcCtD
Dabrafenib—Dry skin—Fluorouracil—skin cancer	0.000133	0.00115	CcSEcCtD
Dabrafenib—Dry mouth—Imiquimod—skin cancer	0.000132	0.00114	CcSEcCtD
Dabrafenib—Decreased appetite—Vemurafenib—skin cancer	0.000132	0.00114	CcSEcCtD
Dabrafenib—Stomatitis—Dactinomycin—skin cancer	0.000131	0.00113	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000131	0.00113	CcSEcCtD
Dabrafenib—Fatigue—Vemurafenib—skin cancer	0.000131	0.00113	CcSEcCtD
Dabrafenib—Neoplasm—Docetaxel—skin cancer	0.000131	0.00113	CcSEcCtD
Dabrafenib—Haemoglobin—Bleomycin—skin cancer	0.00013	0.00113	CcSEcCtD
Dabrafenib—Nasopharyngitis—Fluorouracil—skin cancer	0.00013	0.00113	CcSEcCtD
Dabrafenib—Constipation—Vemurafenib—skin cancer	0.00013	0.00112	CcSEcCtD
Dabrafenib—Oedema—Imiquimod—skin cancer	0.000129	0.00112	CcSEcCtD
Dabrafenib—Haemorrhage—Bleomycin—skin cancer	0.000129	0.00112	CcSEcCtD
Dabrafenib—Infection—Imiquimod—skin cancer	0.000129	0.00111	CcSEcCtD
Dabrafenib—Neutropenia—Temozolomide—skin cancer	0.000128	0.0011	CcSEcCtD
Dabrafenib—Nervous system disorder—Imiquimod—skin cancer	0.000127	0.0011	CcSEcCtD
Dabrafenib—Skin disorder—Imiquimod—skin cancer	0.000126	0.00109	CcSEcCtD
Dabrafenib—Hyperhidrosis—Imiquimod—skin cancer	0.000125	0.00108	CcSEcCtD
Dabrafenib—Hyperglycaemia—Temozolomide—skin cancer	0.000123	0.00107	CcSEcCtD
Dabrafenib—Infestation—Temozolomide—skin cancer	0.000122	0.00105	CcSEcCtD
Dabrafenib—Infestation NOS—Temozolomide—skin cancer	0.000122	0.00105	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Docetaxel—skin cancer	0.000121	0.00104	CcSEcCtD
Dabrafenib—Body temperature increased—Vemurafenib—skin cancer	0.00012	0.00104	CcSEcCtD
Dabrafenib—Stomatitis—Temozolomide—skin cancer	0.000119	0.00103	CcSEcCtD
Dabrafenib—Urinary tract infection—Temozolomide—skin cancer	0.000118	0.00102	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000118	0.00102	CcSEcCtD
Dabrafenib—Insomnia—Imiquimod—skin cancer	0.000117	0.00101	CcSEcCtD
Dabrafenib—Chills—Bleomycin—skin cancer	0.000116	0.00101	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Docetaxel—skin cancer	0.000116	0.001	CcSEcCtD
Dabrafenib—Alopecia—Bleomycin—skin cancer	0.000114	0.00099	CcSEcCtD
Dabrafenib—Erythema—Bleomycin—skin cancer	0.000113	0.000976	CcSEcCtD
Dabrafenib—Decreased appetite—Imiquimod—skin cancer	0.000113	0.000974	CcSEcCtD
Dabrafenib—Infestation—Fluorouracil—skin cancer	0.000112	0.00097	CcSEcCtD
Dabrafenib—Infestation NOS—Fluorouracil—skin cancer	0.000112	0.00097	CcSEcCtD
Dabrafenib—Hypersensitivity—Vemurafenib—skin cancer	0.000112	0.000968	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Imiquimod—skin cancer	0.000112	0.000968	CcSEcCtD
Dabrafenib—Fatigue—Imiquimod—skin cancer	0.000112	0.000966	CcSEcCtD
Dabrafenib—Dermatitis bullous—Docetaxel—skin cancer	0.00011	0.000951	CcSEcCtD
Dabrafenib—Haemoglobin—Temozolomide—skin cancer	0.00011	0.00095	CcSEcCtD
Dabrafenib—Stomatitis—Fluorouracil—skin cancer	0.000109	0.000946	CcSEcCtD
Dabrafenib—Haemorrhage—Temozolomide—skin cancer	0.000109	0.000945	CcSEcCtD
Dabrafenib—Urinary tract infection—Fluorouracil—skin cancer	0.000109	0.000943	CcSEcCtD
Dabrafenib—Asthenia—Vemurafenib—skin cancer	0.000109	0.000943	CcSEcCtD
Dabrafenib—Chills—Dactinomycin—skin cancer	0.000108	0.000938	CcSEcCtD
Dabrafenib—Urinary tract disorder—Temozolomide—skin cancer	0.000108	0.000934	CcSEcCtD
Dabrafenib—Oedema peripheral—Temozolomide—skin cancer	0.000108	0.000931	CcSEcCtD
Dabrafenib—Pruritus—Vemurafenib—skin cancer	0.000107	0.00093	CcSEcCtD
Dabrafenib—Connective tissue disorder—Temozolomide—skin cancer	0.000107	0.000929	CcSEcCtD
Dabrafenib—Urethral disorder—Temozolomide—skin cancer	0.000107	0.000927	CcSEcCtD
Dabrafenib—Alopecia—Dactinomycin—skin cancer	0.000107	0.000924	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Imiquimod—skin cancer	0.000106	0.000916	CcSEcCtD
Dabrafenib—Epistaxis—Fluorouracil—skin cancer	0.000106	0.000915	CcSEcCtD
Dabrafenib—Hyponatraemia—Docetaxel—skin cancer	0.000105	0.000912	CcSEcCtD
Dabrafenib—Erythema—Dactinomycin—skin cancer	0.000105	0.00091	CcSEcCtD
Dabrafenib—Pain in extremity—Docetaxel—skin cancer	0.000105	0.000909	CcSEcCtD
Dabrafenib—Anaemia—Bleomycin—skin cancer	0.000104	0.000902	CcSEcCtD
Dabrafenib—Diarrhoea—Vemurafenib—skin cancer	0.000104	0.000899	CcSEcCtD
Dabrafenib—Body temperature increased—Imiquimod—skin cancer	0.000102	0.000886	CcSEcCtD
Dabrafenib—Abdominal pain—Imiquimod—skin cancer	0.000102	0.000886	CcSEcCtD
Dabrafenib—Eye disorder—Temozolomide—skin cancer	0.000102	0.000883	CcSEcCtD
Dabrafenib—Haemoglobin—Fluorouracil—skin cancer	0.000101	0.000875	CcSEcCtD
Dabrafenib—Leukopenia—Bleomycin—skin cancer	0.000101	0.000873	CcSEcCtD
Dabrafenib—Haemorrhage—Fluorouracil—skin cancer	0.000101	0.000871	CcSEcCtD
Dabrafenib—Dizziness—Vemurafenib—skin cancer	0.0001	0.000869	CcSEcCtD
Dabrafenib—Angiopathy—Temozolomide—skin cancer	9.91e-05	0.000858	CcSEcCtD
Dabrafenib—Immune system disorder—Temozolomide—skin cancer	9.87e-05	0.000854	CcSEcCtD
Dabrafenib—Mediastinal disorder—Temozolomide—skin cancer	9.84e-05	0.000852	CcSEcCtD
Dabrafenib—Cough—Bleomycin—skin cancer	9.84e-05	0.000851	CcSEcCtD
Dabrafenib—CYP3A4—female reproductive system—skin cancer	9.82e-05	0.0078	CbGeAlD
Dabrafenib—Chills—Temozolomide—skin cancer	9.8e-05	0.000848	CcSEcCtD
Dabrafenib—Dehydration—Docetaxel—skin cancer	9.76e-05	0.000845	CcSEcCtD
Dabrafenib—Anaemia—Dactinomycin—skin cancer	9.72e-05	0.000841	CcSEcCtD
Dabrafenib—Vomiting—Vemurafenib—skin cancer	9.65e-05	0.000836	CcSEcCtD
Dabrafenib—Alopecia—Temozolomide—skin cancer	9.65e-05	0.000835	CcSEcCtD
Dabrafenib—Dry skin—Docetaxel—skin cancer	9.62e-05	0.000833	CcSEcCtD
Dabrafenib—Myalgia—Bleomycin—skin cancer	9.6e-05	0.000831	CcSEcCtD
Dabrafenib—Abdominal pain upper—Docetaxel—skin cancer	9.59e-05	0.00083	CcSEcCtD
Dabrafenib—Rash—Vemurafenib—skin cancer	9.57e-05	0.000829	CcSEcCtD
Dabrafenib—Mental disorder—Temozolomide—skin cancer	9.57e-05	0.000828	CcSEcCtD
Dabrafenib—Dermatitis—Vemurafenib—skin cancer	9.57e-05	0.000828	CcSEcCtD
Dabrafenib—Hypersensitivity—Imiquimod—skin cancer	9.54e-05	0.000826	CcSEcCtD
Dabrafenib—Headache—Vemurafenib—skin cancer	9.51e-05	0.000823	CcSEcCtD
Dabrafenib—Erythema—Temozolomide—skin cancer	9.51e-05	0.000823	CcSEcCtD
Dabrafenib—Malnutrition—Temozolomide—skin cancer	9.51e-05	0.000823	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Docetaxel—skin cancer	9.46e-05	0.000818	CcSEcCtD
Dabrafenib—Leukopenia—Dactinomycin—skin cancer	9.41e-05	0.000814	CcSEcCtD
Dabrafenib—Nasopharyngitis—Docetaxel—skin cancer	9.39e-05	0.000813	CcSEcCtD
Dabrafenib—ABCB1—epithelium—skin cancer	9.35e-05	0.00743	CbGeAlD
Dabrafenib—Asthenia—Imiquimod—skin cancer	9.29e-05	0.000804	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Docetaxel—skin cancer	9.26e-05	0.000801	CcSEcCtD
Dabrafenib—Oedema—Bleomycin—skin cancer	9.2e-05	0.000796	CcSEcCtD
Dabrafenib—Back pain—Temozolomide—skin cancer	9.2e-05	0.000796	CcSEcCtD
Dabrafenib—Pruritus—Imiquimod—skin cancer	9.16e-05	0.000793	CcSEcCtD
Dabrafenib—Infection—Bleomycin—skin cancer	9.14e-05	0.000791	CcSEcCtD
Dabrafenib—Nausea—Vemurafenib—skin cancer	9.02e-05	0.000781	CcSEcCtD
Dabrafenib—Thrombocytopenia—Bleomycin—skin cancer	9.01e-05	0.00078	CcSEcCtD
Dabrafenib—Arrhythmia—Fluorouracil—skin cancer	8.99e-05	0.000778	CcSEcCtD
Dabrafenib—Vision blurred—Temozolomide—skin cancer	8.96e-05	0.000776	CcSEcCtD
Dabrafenib—Myalgia—Dactinomycin—skin cancer	8.95e-05	0.000775	CcSEcCtD
Dabrafenib—Alopecia—Fluorouracil—skin cancer	8.89e-05	0.00077	CcSEcCtD
Dabrafenib—Diarrhoea—Imiquimod—skin cancer	8.86e-05	0.000767	CcSEcCtD
Dabrafenib—Anaemia—Temozolomide—skin cancer	8.79e-05	0.000761	CcSEcCtD
Dabrafenib—Erythema—Fluorouracil—skin cancer	8.76e-05	0.000758	CcSEcCtD
Dabrafenib—Hypotension—Bleomycin—skin cancer	8.6e-05	0.000744	CcSEcCtD
Dabrafenib—Oedema—Dactinomycin—skin cancer	8.58e-05	0.000743	CcSEcCtD
Dabrafenib—Dizziness—Imiquimod—skin cancer	8.56e-05	0.000741	CcSEcCtD
Dabrafenib—Infection—Dactinomycin—skin cancer	8.52e-05	0.000738	CcSEcCtD
Dabrafenib—Leukopenia—Temozolomide—skin cancer	8.51e-05	0.000737	CcSEcCtD
Dabrafenib—Neutropenia—Docetaxel—skin cancer	8.49e-05	0.000734	CcSEcCtD
Dabrafenib—Thrombocytopenia—Dactinomycin—skin cancer	8.4e-05	0.000727	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Bleomycin—skin cancer	8.38e-05	0.000725	CcSEcCtD
Dabrafenib—Cough—Temozolomide—skin cancer	8.3e-05	0.000718	CcSEcCtD
Dabrafenib—Vision blurred—Fluorouracil—skin cancer	8.26e-05	0.000715	CcSEcCtD
Dabrafenib—ABCG2—lymph node—skin cancer	8.24e-05	0.00655	CbGeAlD
Dabrafenib—Vomiting—Imiquimod—skin cancer	8.23e-05	0.000713	CcSEcCtD
Dabrafenib—Hypertension—Temozolomide—skin cancer	8.21e-05	0.000711	CcSEcCtD
Dabrafenib—Rash—Imiquimod—skin cancer	8.16e-05	0.000707	CcSEcCtD
Dabrafenib—Dermatitis—Imiquimod—skin cancer	8.16e-05	0.000706	CcSEcCtD
Dabrafenib—ABCB1—mammalian vulva—skin cancer	8.11e-05	0.00645	CbGeAlD
Dabrafenib—Headache—Imiquimod—skin cancer	8.11e-05	0.000702	CcSEcCtD
Dabrafenib—Anaemia—Fluorouracil—skin cancer	8.1e-05	0.000701	CcSEcCtD
Dabrafenib—Arthralgia—Temozolomide—skin cancer	8.1e-05	0.000701	CcSEcCtD
Dabrafenib—Myalgia—Temozolomide—skin cancer	8.1e-05	0.000701	CcSEcCtD
Dabrafenib—Infestation NOS—Docetaxel—skin cancer	8.09e-05	0.0007	CcSEcCtD
Dabrafenib—Infestation—Docetaxel—skin cancer	8.09e-05	0.0007	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	8.04e-05	0.000696	CcSEcCtD
Dabrafenib—Decreased appetite—Bleomycin—skin cancer	8e-05	0.000692	CcSEcCtD
Dabrafenib—Renal failure—Docetaxel—skin cancer	7.95e-05	0.000688	CcSEcCtD
Dabrafenib—Dry mouth—Temozolomide—skin cancer	7.92e-05	0.000685	CcSEcCtD
Dabrafenib—Stomatitis—Docetaxel—skin cancer	7.89e-05	0.000683	CcSEcCtD
Dabrafenib—Leukopenia—Fluorouracil—skin cancer	7.84e-05	0.000679	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dactinomycin—skin cancer	7.82e-05	0.000677	CcSEcCtD
Dabrafenib—Oedema—Temozolomide—skin cancer	7.76e-05	0.000672	CcSEcCtD
Dabrafenib—Infection—Temozolomide—skin cancer	7.71e-05	0.000667	CcSEcCtD
Dabrafenib—Nausea—Imiquimod—skin cancer	7.69e-05	0.000666	CcSEcCtD
Dabrafenib—Epistaxis—Docetaxel—skin cancer	7.63e-05	0.000661	CcSEcCtD
Dabrafenib—Nervous system disorder—Temozolomide—skin cancer	7.61e-05	0.000659	CcSEcCtD
Dabrafenib—Thrombocytopenia—Temozolomide—skin cancer	7.6e-05	0.000658	CcSEcCtD
Dabrafenib—Skin disorder—Temozolomide—skin cancer	7.54e-05	0.000652	CcSEcCtD
Dabrafenib—Hyperhidrosis—Temozolomide—skin cancer	7.5e-05	0.000649	CcSEcCtD
Dabrafenib—Myalgia—Fluorouracil—skin cancer	7.46e-05	0.000646	CcSEcCtD
Dabrafenib—Decreased appetite—Dactinomycin—skin cancer	7.46e-05	0.000646	CcSEcCtD
Dabrafenib—Fatigue—Dactinomycin—skin cancer	7.4e-05	0.00064	CcSEcCtD
Dabrafenib—Haemoglobin—Docetaxel—skin cancer	7.3e-05	0.000632	CcSEcCtD
Dabrafenib—Body temperature increased—Bleomycin—skin cancer	7.27e-05	0.000629	CcSEcCtD
Dabrafenib—Haemorrhage—Docetaxel—skin cancer	7.26e-05	0.000629	CcSEcCtD
Dabrafenib—ABCB1—lymphoid tissue—skin cancer	7.2e-05	0.00573	CbGeAlD
Dabrafenib—Urinary tract disorder—Docetaxel—skin cancer	7.17e-05	0.000621	CcSEcCtD
Dabrafenib—Oedema peripheral—Docetaxel—skin cancer	7.16e-05	0.000619	CcSEcCtD
Dabrafenib—Oedema—Fluorouracil—skin cancer	7.15e-05	0.000619	CcSEcCtD
Dabrafenib—Connective tissue disorder—Docetaxel—skin cancer	7.14e-05	0.000618	CcSEcCtD
Dabrafenib—Urethral disorder—Docetaxel—skin cancer	7.12e-05	0.000616	CcSEcCtD
Dabrafenib—Infection—Fluorouracil—skin cancer	7.1e-05	0.000615	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Temozolomide—skin cancer	7.07e-05	0.000612	CcSEcCtD
Dabrafenib—Insomnia—Temozolomide—skin cancer	7.02e-05	0.000607	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dactinomycin—skin cancer	7.02e-05	0.000607	CcSEcCtD
Dabrafenib—Nervous system disorder—Fluorouracil—skin cancer	7.01e-05	0.000607	CcSEcCtD
Dabrafenib—Thrombocytopenia—Fluorouracil—skin cancer	7e-05	0.000606	CcSEcCtD
Dabrafenib—ABCB1—female reproductive system—skin cancer	6.95e-05	0.00552	CbGeAlD
Dabrafenib—Eye disorder—Docetaxel—skin cancer	6.79e-05	0.000588	CcSEcCtD
Dabrafenib—Abdominal pain—Dactinomycin—skin cancer	6.78e-05	0.000587	CcSEcCtD
Dabrafenib—Body temperature increased—Dactinomycin—skin cancer	6.78e-05	0.000587	CcSEcCtD
Dabrafenib—Hypersensitivity—Bleomycin—skin cancer	6.78e-05	0.000587	CcSEcCtD
Dabrafenib—Decreased appetite—Temozolomide—skin cancer	6.75e-05	0.000584	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Temozolomide—skin cancer	6.7e-05	0.00058	CcSEcCtD
Dabrafenib—Fatigue—Temozolomide—skin cancer	6.69e-05	0.000579	CcSEcCtD
Dabrafenib—Hypotension—Fluorouracil—skin cancer	6.68e-05	0.000578	CcSEcCtD
Dabrafenib—Constipation—Temozolomide—skin cancer	6.64e-05	0.000574	CcSEcCtD
Dabrafenib—Asthenia—Bleomycin—skin cancer	6.6e-05	0.000571	CcSEcCtD
Dabrafenib—Angiopathy—Docetaxel—skin cancer	6.59e-05	0.00057	CcSEcCtD
Dabrafenib—Immune system disorder—Docetaxel—skin cancer	6.56e-05	0.000568	CcSEcCtD
Dabrafenib—Mediastinal disorder—Docetaxel—skin cancer	6.55e-05	0.000567	CcSEcCtD
Dabrafenib—Chills—Docetaxel—skin cancer	6.52e-05	0.000564	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Fluorouracil—skin cancer	6.51e-05	0.000564	CcSEcCtD
Dabrafenib—Pruritus—Bleomycin—skin cancer	6.51e-05	0.000563	CcSEcCtD
Dabrafenib—Arrhythmia—Docetaxel—skin cancer	6.49e-05	0.000562	CcSEcCtD
Dabrafenib—Insomnia—Fluorouracil—skin cancer	6.47e-05	0.00056	CcSEcCtD
Dabrafenib—Alopecia—Docetaxel—skin cancer	6.42e-05	0.000556	CcSEcCtD
Dabrafenib—Mental disorder—Docetaxel—skin cancer	6.36e-05	0.000551	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Temozolomide—skin cancer	6.35e-05	0.000549	CcSEcCtD
Dabrafenib—Malnutrition—Docetaxel—skin cancer	6.32e-05	0.000547	CcSEcCtD
Dabrafenib—Erythema—Docetaxel—skin cancer	6.32e-05	0.000547	CcSEcCtD
Dabrafenib—Hypersensitivity—Dactinomycin—skin cancer	6.32e-05	0.000547	CcSEcCtD
Dabrafenib—Decreased appetite—Fluorouracil—skin cancer	6.22e-05	0.000538	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Fluorouracil—skin cancer	6.17e-05	0.000534	CcSEcCtD
Dabrafenib—Asthenia—Dactinomycin—skin cancer	6.16e-05	0.000533	CcSEcCtD
Dabrafenib—Abdominal pain—Temozolomide—skin cancer	6.13e-05	0.000531	CcSEcCtD
Dabrafenib—Body temperature increased—Temozolomide—skin cancer	6.13e-05	0.000531	CcSEcCtD
Dabrafenib—Back pain—Docetaxel—skin cancer	6.12e-05	0.000529	CcSEcCtD
Dabrafenib—Muscle spasms—Docetaxel—skin cancer	6.08e-05	0.000526	CcSEcCtD
Dabrafenib—Diarrhoea—Dactinomycin—skin cancer	5.87e-05	0.000508	CcSEcCtD
Dabrafenib—Vomiting—Bleomycin—skin cancer	5.85e-05	0.000506	CcSEcCtD
Dabrafenib—Anaemia—Docetaxel—skin cancer	5.84e-05	0.000506	CcSEcCtD
Dabrafenib—ABCB1—head—skin cancer	5.81e-05	0.00461	CbGeAlD
Dabrafenib—Rash—Bleomycin—skin cancer	5.8e-05	0.000502	CcSEcCtD
Dabrafenib—Dermatitis—Bleomycin—skin cancer	5.8e-05	0.000502	CcSEcCtD
Dabrafenib—Hypersensitivity—Temozolomide—skin cancer	5.72e-05	0.000495	CcSEcCtD
Dabrafenib—Leukopenia—Docetaxel—skin cancer	5.66e-05	0.00049	CcSEcCtD
Dabrafenib—Body temperature increased—Fluorouracil—skin cancer	5.65e-05	0.000489	CcSEcCtD
Dabrafenib—Asthenia—Temozolomide—skin cancer	5.57e-05	0.000482	CcSEcCtD
Dabrafenib—Cough—Docetaxel—skin cancer	5.52e-05	0.000478	CcSEcCtD
Dabrafenib—Pruritus—Temozolomide—skin cancer	5.49e-05	0.000475	CcSEcCtD
Dabrafenib—Nausea—Bleomycin—skin cancer	5.46e-05	0.000473	CcSEcCtD
Dabrafenib—Hypertension—Docetaxel—skin cancer	5.46e-05	0.000472	CcSEcCtD
Dabrafenib—Vomiting—Dactinomycin—skin cancer	5.46e-05	0.000472	CcSEcCtD
Dabrafenib—Rash—Dactinomycin—skin cancer	5.41e-05	0.000468	CcSEcCtD
Dabrafenib—Arthralgia—Docetaxel—skin cancer	5.38e-05	0.000466	CcSEcCtD
Dabrafenib—Myalgia—Docetaxel—skin cancer	5.38e-05	0.000466	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	5.35e-05	0.000463	CcSEcCtD
Dabrafenib—Diarrhoea—Temozolomide—skin cancer	5.31e-05	0.00046	CcSEcCtD
Dabrafenib—Hypersensitivity—Fluorouracil—skin cancer	5.27e-05	0.000456	CcSEcCtD
Dabrafenib—Dry mouth—Docetaxel—skin cancer	5.26e-05	0.000456	CcSEcCtD
Dabrafenib—Oedema—Docetaxel—skin cancer	5.16e-05	0.000447	CcSEcCtD
Dabrafenib—Dizziness—Temozolomide—skin cancer	5.13e-05	0.000444	CcSEcCtD
Dabrafenib—Infection—Docetaxel—skin cancer	5.13e-05	0.000444	CcSEcCtD
Dabrafenib—Nausea—Dactinomycin—skin cancer	5.1e-05	0.000441	CcSEcCtD
Dabrafenib—Nervous system disorder—Docetaxel—skin cancer	5.06e-05	0.000438	CcSEcCtD
Dabrafenib—Pruritus—Fluorouracil—skin cancer	5.06e-05	0.000438	CcSEcCtD
Dabrafenib—Thrombocytopenia—Docetaxel—skin cancer	5.05e-05	0.000437	CcSEcCtD
Dabrafenib—Skin disorder—Docetaxel—skin cancer	5.01e-05	0.000434	CcSEcCtD
Dabrafenib—Vomiting—Temozolomide—skin cancer	4.93e-05	0.000427	CcSEcCtD
Dabrafenib—Rash—Temozolomide—skin cancer	4.89e-05	0.000423	CcSEcCtD
Dabrafenib—Diarrhoea—Fluorouracil—skin cancer	4.89e-05	0.000423	CcSEcCtD
Dabrafenib—Dermatitis—Temozolomide—skin cancer	4.89e-05	0.000423	CcSEcCtD
Dabrafenib—Headache—Temozolomide—skin cancer	4.86e-05	0.000421	CcSEcCtD
Dabrafenib—Hypotension—Docetaxel—skin cancer	4.82e-05	0.000417	CcSEcCtD
Dabrafenib—Dizziness—Fluorouracil—skin cancer	4.73e-05	0.000409	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Docetaxel—skin cancer	4.7e-05	0.000407	CcSEcCtD
Dabrafenib—Insomnia—Docetaxel—skin cancer	4.67e-05	0.000404	CcSEcCtD
Dabrafenib—Nausea—Temozolomide—skin cancer	4.61e-05	0.000399	CcSEcCtD
Dabrafenib—Vomiting—Fluorouracil—skin cancer	4.55e-05	0.000393	CcSEcCtD
Dabrafenib—Rash—Fluorouracil—skin cancer	4.51e-05	0.00039	CcSEcCtD
Dabrafenib—Dermatitis—Fluorouracil—skin cancer	4.5e-05	0.00039	CcSEcCtD
Dabrafenib—Decreased appetite—Docetaxel—skin cancer	4.49e-05	0.000388	CcSEcCtD
Dabrafenib—Headache—Fluorouracil—skin cancer	4.48e-05	0.000388	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Docetaxel—skin cancer	4.46e-05	0.000386	CcSEcCtD
Dabrafenib—Fatigue—Docetaxel—skin cancer	4.45e-05	0.000385	CcSEcCtD
Dabrafenib—Constipation—Docetaxel—skin cancer	4.41e-05	0.000382	CcSEcCtD
Dabrafenib—Nausea—Fluorouracil—skin cancer	4.25e-05	0.000368	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Docetaxel—skin cancer	4.22e-05	0.000365	CcSEcCtD
Dabrafenib—Body temperature increased—Docetaxel—skin cancer	4.08e-05	0.000353	CcSEcCtD
Dabrafenib—Abdominal pain—Docetaxel—skin cancer	4.08e-05	0.000353	CcSEcCtD
Dabrafenib—ABCB1—lymph node—skin cancer	4.06e-05	0.00323	CbGeAlD
Dabrafenib—Hypersensitivity—Docetaxel—skin cancer	3.8e-05	0.000329	CcSEcCtD
Dabrafenib—Asthenia—Docetaxel—skin cancer	3.7e-05	0.00032	CcSEcCtD
Dabrafenib—Pruritus—Docetaxel—skin cancer	3.65e-05	0.000316	CcSEcCtD
Dabrafenib—Diarrhoea—Docetaxel—skin cancer	3.53e-05	0.000306	CcSEcCtD
Dabrafenib—Dizziness—Docetaxel—skin cancer	3.41e-05	0.000295	CcSEcCtD
Dabrafenib—Vomiting—Docetaxel—skin cancer	3.28e-05	0.000284	CcSEcCtD
Dabrafenib—Rash—Docetaxel—skin cancer	3.25e-05	0.000282	CcSEcCtD
Dabrafenib—Dermatitis—Docetaxel—skin cancer	3.25e-05	0.000281	CcSEcCtD
Dabrafenib—Headache—Docetaxel—skin cancer	3.23e-05	0.00028	CcSEcCtD
Dabrafenib—Nausea—Docetaxel—skin cancer	3.07e-05	0.000265	CcSEcCtD
Dabrafenib—BRAF—Signaling Pathways—GLI2—skin cancer	2.6e-05	0.000582	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—NRAS—skin cancer	2.6e-05	0.000582	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—NRAS—skin cancer	2.6e-05	0.000582	CbGpPWpGaD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—KRAS—skin cancer	2.58e-05	0.000576	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—HRAS—skin cancer	2.57e-05	0.000575	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—HRAS—skin cancer	2.57e-05	0.000575	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CSPG4—skin cancer	2.57e-05	0.000575	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—NRAS—skin cancer	2.56e-05	0.000573	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	2.55e-05	0.00057	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—NRAS—skin cancer	2.55e-05	0.000569	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FOXO4—skin cancer	2.54e-05	0.000569	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SHH—skin cancer	2.53e-05	0.000565	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ENO2—skin cancer	2.53e-05	0.000565	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—HRAS—skin cancer	2.52e-05	0.000563	CbGpPWpGaD
Dabrafenib—RAF1—ErbB1 downstream signaling—HRAS—skin cancer	2.52e-05	0.000563	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PLIN2—skin cancer	2.52e-05	0.000563	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—BRAF—skin cancer	2.51e-05	0.00056	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	2.5e-05	0.000559	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MC1R—skin cancer	2.48e-05	0.000555	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—KRAS—skin cancer	2.48e-05	0.000555	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	2.48e-05	0.000555	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—IL6—skin cancer	2.46e-05	0.000551	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—HRAS—skin cancer	2.46e-05	0.000551	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—BRAF—skin cancer	2.46e-05	0.000549	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GLI1—skin cancer	2.45e-05	0.000547	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—NRAS—skin cancer	2.45e-05	0.000547	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—NRAS—skin cancer	2.43e-05	0.000544	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—NRAS—skin cancer	2.42e-05	0.000541	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IL6—skin cancer	2.41e-05	0.000539	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—NRAS—skin cancer	2.41e-05	0.000539	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—HRAS—skin cancer	2.4e-05	0.000536	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTCH2—skin cancer	2.38e-05	0.000531	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—IL6—skin cancer	2.37e-05	0.000531	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—NRAS—skin cancer	2.36e-05	0.000529	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL6—skin cancer	2.36e-05	0.000527	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—HRAS—skin cancer	2.34e-05	0.000524	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—KRAS—skin cancer	2.34e-05	0.000523	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PLIN2—skin cancer	2.33e-05	0.000521	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—HRAS—skin cancer	2.33e-05	0.00052	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SUFU—skin cancer	2.32e-05	0.000519	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—IL6—skin cancer	2.29e-05	0.000513	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—NRAS—skin cancer	2.27e-05	0.000507	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	2.27e-05	0.000507	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—NRAS—skin cancer	2.27e-05	0.000507	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—HRAS—skin cancer	2.27e-05	0.000506	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—NRAS—skin cancer	2.25e-05	0.000502	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—IL6—skin cancer	2.24e-05	0.000501	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—KRAS—skin cancer	2.24e-05	0.000501	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—KRAS—skin cancer	2.24e-05	0.000501	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—NRAS—skin cancer	2.23e-05	0.000499	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—NRAS—skin cancer	2.23e-05	0.000498	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—IL6—skin cancer	2.23e-05	0.000498	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—NRAS—skin cancer	2.22e-05	0.000496	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—KRAS—skin cancer	2.2e-05	0.000493	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—skin cancer	2.19e-05	0.00049	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—KRAS—skin cancer	2.19e-05	0.00049	CbGpPWpGaD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—HRAS—skin cancer	2.19e-05	0.00049	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—HRAS—skin cancer	2.17e-05	0.000486	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	2.12e-05	0.000475	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—HRAS—skin cancer	2.11e-05	0.000472	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—KRAS—skin cancer	2.11e-05	0.000471	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—KRAS—skin cancer	2.09e-05	0.000468	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—KRAS—skin cancer	2.09e-05	0.000468	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—KRAS—skin cancer	2.08e-05	0.000466	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—KRAS—skin cancer	2.07e-05	0.000464	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—SHH—skin cancer	2.07e-05	0.000463	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FOXO4—skin cancer	2.06e-05	0.000461	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ENO2—skin cancer	2.05e-05	0.000459	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—KRAS—skin cancer	2.03e-05	0.000455	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	2.03e-05	0.000454	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CSPG4—skin cancer	2.03e-05	0.000454	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—IL6—skin cancer	2.02e-05	0.000451	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	2.01e-05	0.000449	CbGpPWpGaD
Dabrafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	2e-05	0.000447	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—HRAS—skin cancer	1.99e-05	0.000445	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—SMO—skin cancer	1.96e-05	0.000439	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PTCH1—skin cancer	1.96e-05	0.000439	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—HRAS—skin cancer	1.96e-05	0.000437	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—KRAS—skin cancer	1.95e-05	0.000436	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—KRAS—skin cancer	1.95e-05	0.000436	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	1.95e-05	0.000436	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.94e-05	0.000434	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—KRAS—skin cancer	1.93e-05	0.000432	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—KRAS—skin cancer	1.92e-05	0.00043	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—KRAS—skin cancer	1.92e-05	0.000429	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PTGER4—skin cancer	1.91e-05	0.000428	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—KRAS—skin cancer	1.91e-05	0.000427	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—IL6—skin cancer	1.9e-05	0.000426	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—HRAS—skin cancer	1.9e-05	0.000426	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CSPG4—skin cancer	1.88e-05	0.00042	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—HRAS—skin cancer	1.87e-05	0.000419	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—HRAS—skin cancer	1.86e-05	0.000417	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.84e-05	0.000411	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—IL6—skin cancer	1.82e-05	0.000407	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.81e-05	0.000405	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—skin cancer	1.81e-05	0.000404	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GLI2—skin cancer	1.8e-05	0.000403	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—HRAS—skin cancer	1.8e-05	0.000402	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CDK4—skin cancer	1.79e-05	0.000401	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—IL6—skin cancer	1.79e-05	0.000401	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—HRAS—skin cancer	1.79e-05	0.0004	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IL6—skin cancer	1.78e-05	0.000399	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—HRAS—skin cancer	1.78e-05	0.000398	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—HRAS—skin cancer	1.78e-05	0.000398	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—HRAS—skin cancer	1.77e-05	0.000396	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SHH—skin cancer	1.77e-05	0.000396	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—HRAS—skin cancer	1.76e-05	0.000394	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RASA1—skin cancer	1.76e-05	0.000393	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ENO2—skin cancer	1.75e-05	0.000391	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SHH—skin cancer	1.75e-05	0.000391	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	1.73e-05	0.000386	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MC1R—skin cancer	1.72e-05	0.000384	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—IL6—skin cancer	1.71e-05	0.000383	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—IL6—skin cancer	1.7e-05	0.000381	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—IL6—skin cancer	1.7e-05	0.000379	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GLI1—skin cancer	1.69e-05	0.000379	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—IL6—skin cancer	1.69e-05	0.000377	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SMO—skin cancer	1.68e-05	0.000375	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTCH1—skin cancer	1.68e-05	0.000375	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.67e-05	0.000373	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—HRAS—skin cancer	1.67e-05	0.000372	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—HRAS—skin cancer	1.66e-05	0.000371	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	1.66e-05	0.000371	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—HRAS—skin cancer	1.66e-05	0.000371	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—HRAS—skin cancer	1.64e-05	0.000368	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—HRAS—skin cancer	1.63e-05	0.000365	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTGER4—skin cancer	1.63e-05	0.000365	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.63e-05	0.000365	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—HRAS—skin cancer	1.63e-05	0.000364	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—HRAS—skin cancer	1.62e-05	0.000363	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.61e-05	0.000359	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SUFU—skin cancer	1.61e-05	0.000359	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—IL6—skin cancer	1.59e-05	0.000355	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	1.59e-05	0.000355	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—IL6—skin cancer	1.59e-05	0.000355	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—IL6—skin cancer	1.57e-05	0.000352	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—NRAS—skin cancer	1.57e-05	0.000351	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—HRAS—skin cancer	1.57e-05	0.00035	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—IL6—skin cancer	1.56e-05	0.00035	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—IL6—skin cancer	1.56e-05	0.000349	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—IL6—skin cancer	1.55e-05	0.000347	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—NRAS—skin cancer	1.54e-05	0.000345	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FOXO4—skin cancer	1.54e-05	0.000345	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—HRAS—skin cancer	1.5e-05	0.000336	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—NRAS—skin cancer	1.48e-05	0.000332	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	1.47e-05	0.000328	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ERCC2—skin cancer	1.47e-05	0.000328	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PLIN2—skin cancer	1.45e-05	0.000323	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FOXO4—skin cancer	1.44e-05	0.000323	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FOXO4—skin cancer	1.43e-05	0.000319	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.42e-05	0.000317	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	1.41e-05	0.000314	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—NRAS—skin cancer	1.4e-05	0.000313	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ENO2—skin cancer	1.38e-05	0.000308	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TERT—skin cancer	1.38e-05	0.000308	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.36e-05	0.000304	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—KRAS—skin cancer	1.35e-05	0.000302	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—KRAS—skin cancer	1.33e-05	0.000297	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	1.29e-05	0.000289	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ENO2—skin cancer	1.28e-05	0.000286	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—KRAS—skin cancer	1.28e-05	0.000285	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLIN2—skin cancer	1.26e-05	0.000282	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SHH—skin cancer	1.22e-05	0.000274	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RASA1—skin cancer	1.22e-05	0.000272	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—KRAS—skin cancer	1.2e-05	0.000269	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ERCC2—skin cancer	1.19e-05	0.000267	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CSPG4—skin cancer	1.17e-05	0.000261	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTCH1—skin cancer	1.16e-05	0.000259	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SMO—skin cancer	1.16e-05	0.000259	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—HRAS—skin cancer	1.15e-05	0.000258	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HRAS—skin cancer	1.15e-05	0.000257	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—HRAS—skin cancer	1.13e-05	0.000253	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTGER4—skin cancer	1.13e-05	0.000253	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—skin cancer	1.1e-05	0.000246	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HRAS—skin cancer	1.09e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—skin cancer	1.08e-05	0.000242	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.08e-05	0.000241	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—skin cancer	1.04e-05	0.000232	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—HRAS—skin cancer	1.02e-05	0.000229	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CSPG4—skin cancer	1.02e-05	0.000227	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERCC2—skin cancer	1.02e-05	0.000227	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FOXO4—skin cancer	9.98e-06	0.000223	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—NRAS—skin cancer	9.98e-06	0.000223	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—skin cancer	9.79e-06	0.000219	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NRAS—skin cancer	9.79e-06	0.000219	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TERT—skin cancer	9.63e-06	0.000215	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TERT—skin cancer	9.52e-06	0.000213	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NRAS—skin cancer	8.81e-06	0.000197	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—skin cancer	8.8e-06	0.000197	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	8.66e-06	0.000194	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KRAS—skin cancer	8.59e-06	0.000192	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NRAS—skin cancer	8.46e-06	0.000189	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—KRAS—skin cancer	8.42e-06	0.000188	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ERCC2—skin cancer	8.01e-06	0.000179	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ENO2—skin cancer	7.92e-06	0.000177	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLIN2—skin cancer	7.76e-06	0.000174	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	7.7e-06	0.000172	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KRAS—skin cancer	7.58e-06	0.00017	CbGpPWpGaD
Dabrafenib—RAF1—Disease—BRAF—skin cancer	7.54e-06	0.000169	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—skin cancer	7.49e-06	0.000167	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ERCC2—skin cancer	7.42e-06	0.000166	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HRAS—skin cancer	7.3e-06	0.000163	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KRAS—skin cancer	7.28e-06	0.000163	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HRAS—skin cancer	7.16e-06	0.00016	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—skin cancer	7.15e-06	0.00016	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—skin cancer	6.98e-06	0.000156	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ENO2—skin cancer	6.9e-06	0.000154	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NRAS—skin cancer	6.85e-06	0.000153	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TERT—skin cancer	6.67e-06	0.000149	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—skin cancer	6.44e-06	0.000144	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CSPG4—skin cancer	6.26e-06	0.00014	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.2e-06	0.000139	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—skin cancer	6.19e-06	0.000138	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—skin cancer	6.17e-06	0.000138	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—skin cancer	6.09e-06	0.000136	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—skin cancer	5.89e-06	0.000132	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NRAS—skin cancer	5.62e-06	0.000126	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BRAF—skin cancer	5.28e-06	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NRAS—skin cancer	5.13e-06	0.000115	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—skin cancer	5.01e-06	0.000112	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—skin cancer	4.83e-06	0.000108	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—skin cancer	4.8e-06	0.000107	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NRAS—skin cancer	4.79e-06	0.000107	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—skin cancer	4.79e-06	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NRAS—skin cancer	4.74e-06	0.000106	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ERCC2—skin cancer	4.6e-06	0.000103	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—skin cancer	4.45e-06	9.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—skin cancer	4.42e-06	9.87e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO2—skin cancer	4.25e-06	9.51e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—skin cancer	4.13e-06	9.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—skin cancer	4.11e-06	9.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—skin cancer	4.08e-06	9.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ERCC2—skin cancer	4.01e-06	8.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—skin cancer	3.93e-06	8.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—skin cancer	3.75e-06	8.39e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—skin cancer	3.67e-06	8.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—skin cancer	3.59e-06	8.03e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—skin cancer	3.51e-06	7.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—skin cancer	3.47e-06	7.75e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—skin cancer	3.36e-06	7.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NRAS—skin cancer	3.32e-06	7.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—skin cancer	3.32e-06	7.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—skin cancer	2.86e-06	6.38e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—skin cancer	2.76e-06	6.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—skin cancer	2.54e-06	5.67e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ERCC2—skin cancer	2.47e-06	5.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—skin cancer	2.43e-06	5.43e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—skin cancer	2.4e-06	5.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—skin cancer	2.32e-06	5.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—skin cancer	1.48e-06	3.31e-05	CbGpPWpGaD
